Suppr超能文献

肥胖时胰高血糖素样肽-1分泌减弱:是原因还是结果?

Attenuated GLP-1 secretion in obesity: cause or consequence?

作者信息

Ranganath L R, Beety J M, Morgan L M, Wright J W, Howland R, Marks V

机构信息

School of Biological Sciences, University of Surrey, Guildford.

出版信息

Gut. 1996 Jun;38(6):916-9. doi: 10.1136/gut.38.6.916.

Abstract

BACKGROUND

Hypersecretion of insulinotropic factors such as glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-36)amide (GLP-1) have been postulated to account for the hyperinsulinaemia of obesity.

AIMS

To examine the role of GLP-1 and GIP in obese women and matched controls.

SUBJECTS

Six lean and six obese women subjects matched for age.

METHODS

The gut hormone, plasma glucose, and serum triglyceride responses were studied over 180 minutes after oral carbohydrate and fat meals. Heparin (10,000 units) was given intravenously at 120 minutes.

RESULTS

There was pronounced attenuation of plasma GLP-1 secretion to oral carbohydrate in the obese compared with lean subjects but no such difference in response to oral fat load. There were no differences in the plasma GIP responses to carbohydrate or fat feeding. There was an apparent fall in plasma GLP-1 values in all subjects after administration of heparin.

CONCLUSION

Postprandial GLP-1 secretion in response to oral carbohydrate is considerably attenuated in obese subjects. The cause of this attenuation of GLP-1 secretion is not known although we suggest that both this fall and the overall reduction in GLP-1 values in obese subjects may be related to an increase in plasma non-esterified fatty acids.

摘要

背景

胰岛素促分泌因子如葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽-1(7-36)酰胺(GLP-1)分泌过多被认为是肥胖者高胰岛素血症的原因。

目的

研究GLP-1和GIP在肥胖女性及匹配的对照者中的作用。

对象

6名年龄匹配的瘦女性和6名肥胖女性。

方法

研究口服碳水化合物和脂肪餐后180分钟内的肠道激素、血糖和血清甘油三酯反应。在120分钟时静脉注射肝素(10,000单位)。

结果

与瘦受试者相比,肥胖者口服碳水化合物后血浆GLP-1分泌明显减弱,但对口服脂肪负荷的反应无此差异。血浆GIP对碳水化合物或脂肪喂养的反应无差异。注射肝素后,所有受试者的血浆GLP-1值均明显下降。

结论

肥胖受试者餐后口服碳水化合物后GLP-1分泌明显减弱。GLP-1分泌减弱的原因尚不清楚,不过我们认为肥胖者GLP-1值的这种下降及总体降低可能与血浆非酯化脂肪酸增加有关。

相似文献

1
Attenuated GLP-1 secretion in obesity: cause or consequence?
Gut. 1996 Jun;38(6):916-9. doi: 10.1136/gut.38.6.916.
5
The effect of circulating non-esterified fatty acids on the entero-insular axis.
Eur J Clin Invest. 1999 Jan;29(1):27-32. doi: 10.1046/j.1365-2362.1999.00426.x.
6
Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects.
Horm Metab Res. 2001 Jan;33(1):57-61. doi: 10.1055/s-2001-12628.
8
Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
Diabet Med. 1993 Jan-Feb;10(1):44-9. doi: 10.1111/j.1464-5491.1993.tb01995.x.

引用本文的文献

1
New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.
Int J Mol Sci. 2025 Jun 26;26(13):6143. doi: 10.3390/ijms26136143.
2
Effects of beinaglutide on visceral fat area and gut microbiota in obesity.
Eur J Med Res. 2025 Jun 4;30(1):448. doi: 10.1186/s40001-025-02585-5.
4
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease.
Endocr Rev. 2025 Jul 15;46(4):479-500. doi: 10.1210/endrev/bnaf006.
5
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.
Toxicol Rep. 2025 Jan 16;14:101895. doi: 10.1016/j.toxrep.2025.101895. eCollection 2025 Jun.
6
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
Medicine (Baltimore). 2024 Nov 1;103(44):e40364. doi: 10.1097/MD.0000000000040364.
7
Endothelial Dysfunction in Obesity and Therapeutic Targets.
Adv Exp Med Biol. 2024;1460:489-538. doi: 10.1007/978-3-031-63657-8_17.
8
Obesity and the gut microbiota: implications of neuroendocrine and immune signaling.
FEBS J. 2025 Mar;292(6):1397-1420. doi: 10.1111/febs.17249. Epub 2024 Aug 19.
9
The Role of Peptides in Asthma-Obesity Phenotype.
Int J Mol Sci. 2024 Mar 12;25(6):3213. doi: 10.3390/ijms25063213.

本文引用的文献

1
NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.
Lancet. 1964 Jul 4;2(7349):20-1. doi: 10.1016/s0140-6736(64)90011-x.
4
Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
Diabet Med. 1993 Jan-Feb;10(1):44-9. doi: 10.1111/j.1464-5491.1993.tb01995.x.
6
Exon duplication and divergence in the human preproglucagon gene.
Nature. 1983;304(5924):368-71. doi: 10.1038/304368a0.
7
Plasma free fatty acid turnover rate in obesity.
Acta Med Scand. 1969 Apr;185(4):351-6. doi: 10.1111/j.0954-6820.1969.tb07347.x.
8
Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut.
FEBS Lett. 1987 Jan 26;211(2):169-74. doi: 10.1016/0014-5793(87)81430-8.
9
Glucagon-like peptide-1 7-36: a physiological incretin in man.
Lancet. 1987 Dec 5;2(8571):1300-4. doi: 10.1016/s0140-6736(87)91194-9.
10
The enteroinsular axis revisited. A novel role for an incretin.
N Engl J Med. 1992 May 14;326(20):1352-3. doi: 10.1056/NEJM199205143262009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验